Long-Term Oncological Outcome Comparison between Intermediate- and High-Dose Radioactive Iodine Ablation in Patients with Differentiated Thyroid Carcinoma: A Propensity Score Matching Study
Table 1
Comparison of baseline clinicopathological characteristics between intermediate- (100 mCi) and high-dose (150 mCi) groups before and after propensity score matching.
Before matching
value
After matching
value
100 mCi (n = 1146)
150 mCi (n = 302)
100 mCi (n = 276)
150 mCi (n = 276)
Age (years)
46.3 ± 12.2 (range, 11–81)
45.9 ± 12.7 (range, 18–74)
0.599
45.6 ± 13.3 (range, 12–81)
45.6 ± 12.8 (range, 18–74)
0.997
≥55
294 (25.7%)
84 (27.8%)
0.462
201 (72.8%)
202 (73.2%)
0.924
<55
852 (74.3%)
218 (72.2%)
75 (27.2%)
74 (26.8%)
Female
869 (75.8%)
238 (78.8%)
0.287
206 (74.6%)
214 (77.5%)
0.485
Type of carcinoma
0.185
1.000
PTC
1137 (99.2%)
297 (98.3%)
272 (98.6%)
272 (98.6%)
FTC
9 (0.8%)
5 (1.7%)
4 (1.4%)
4 (1.4%)
Extent of operation
0.003
0.616
TT
953 (83.2%)
228 (75.5%)
208 (75.4%)
214 (77.5%)
TT and mRND
193 (16.8%)
74 (24.5%)
68 (24.6%)
62 (22.5%)
Tumor size (cm)
1.2 ± 0.8 (range, 0.2–9.0)
1.4 ± 0.9 (range, 0.2–6.5)
0.001
1.4 ± 0.8 (range, 0.2–5.4)
1.3 ± 0.8 (range, 0.2–6.5)
0.513
ETE
93 (8.1%)
58 (19.2%)
<0.001
48 (17.4%)
40 (14.5%)
0.416
Multifocality
617 (53.8%)
133 (44.0%)
0.003
133 (48.2%)
127 (46.0%)
0.670
Bilaterality
416 (36.3%)
99 (32.8%)
0.280
85 (30.8%)
94 (34.1%)
0.467
Lymphatic invasion
491 (42.8%)
147 (48.7%)
0.078
139 (50.4%)
128 (46.4%)
0.394
Vascular invasion
38 (3.3%)
17 (5.6%)
0.088
15 (5.4%)
15 (5.4%)
1.000
Perineural invasion
28 (2.4%)
19 (6.3%)
0.002
12 (4.3%)
10 (3.6%)
0.828
BRAFV600E positive
700/880 (79.5%)
126/158 (79.7%)
0.954
173/216 (80.1%)
111/140 (79.3%)
0.893
Harvested LNs
19.6 ± 21.6
20.4 ± 21.7
0.554
22.9 ± 23.4
19.5 ± 21.3
0.073
Positive LNs
4.0 ± 5.9
5.2 ± 6.0
0.004
4.9 ± 5.7
4.9 ± 5.9
0.901
ATA risk stratification
<0.001
0.740
Low
273 (23.8%)
48 (15.9%)
47 (17.0%)
51 (18.5%)
Intermediate
787 (68.7%)
197 (65.2%)
184 (66.7%)
186 (67.4%)
High
86 (7.5%)
57 (18.9%)
45 (16.3%)
39 (14.1%)
T stage
<0.001
0.773
T1
953 (83.2%)
215 (71.2%)
200 (72.5%)
208 (75.4%)
T2
85 (7.4%)
27 (8.9%)
27 (9.8%)
26 (9.4%)
T3a
15 (1.3%)
2 (0.7%)
1 (0.4%)
2 (0.7%)
T3b
90 (7.9%)
55 (18.2%)
47 (17.0%)
38 (13.8%)
T4
3 (0.3%)
3 (1.0%)
1 (0.4%)
2 (0.7%)
N stage
<0.001
0.820
N0
284 (24.8%)
52 (17.2%)
47 (17.0%)
50 (18.1%)
N1a
669 (58.4%)
176 (58.3%)
161 (58.3%)
164 (59.4%)
N1b
193 (16.8%)
74 (24.5%)
68 (24.6%)
62 (22.5%)
TNM stage
0.008
0.608
Stage I
939 (81.9%)
228 (75.5%)
218 (79.0%)
212 (76.8%)
0.694
Stage II
207 (18.1%)
73 (24.2%)
58 (21.0%)
64 (23.2%)
Stage III
0 (0%)
1 (0.3%)
0 (0%)
0 (0%)
Recurrence
35 (3.1%)
17 (5.6%)
0.038
15 (5.4%)
12 (4.3%)
Data are expressed as the patient’s number (%) or mean ± SD. A statistically significant difference was defined as . Abbreviation: PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; TT, total thyroidectomy; mRND, modified radical neck dissection; ETE, extrathyroidal extension; LN, lymph node; ATA, American thyroid association; T, tumor; N, node; M, metastasis.
